MedTrace Logo

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

NCT00601003 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2024-08-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether nifurtimox in combination with cyclophosphamide and topotecan are effective in the treatment of relapsed or refractory neuroblastoma and medulloblastoma.

Conditions

Interventions

DRUG

Nifurtimox

30mg/kg/day PO divided into TID dosing q day

DRUG

Cyclophosphamide

250 mg/m2/dose in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.

DRUG

Topotecan

0.75mg/m2/dose, in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Giselle Sholler

    lead OTHER

Principal Investigators

  • Giselle Sholler, MD · Beat Childhood Cancer at Atrium Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-14
Primary Completion
2020-04-28
Completion
2022-10-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00601003 on ClinicalTrials.gov